People who took Pfizer’s antiviral treatment Paxlovid shortly after infection saw a 26% lower risk of long Covid compared with those who didn’t, the study said.
The FDA sees a potential risk and has asked Pfizer to conduct a safety study on Guillain-Barre after a potential approval, which the company said it would do.
Preliminary CDC data indicated a possible stroke risk following simultaneous administration of the Pfizer Covid booster and the flu vaccine.
){kind=link}
){kind=link}
){kind=link}